Dialysis Clinical Trial
Official title:
Constitutive Study of a Serum Bank and Plasma Bank of Healthy Subjects Comparators to Dialysis Subjects (SPSSCD)
To be able to evaluate the predictive value of glycosylated ferritin as a predictive marker of hepatic iron stock in dialysis patients, we need to validate these results with a cohort of healthy volunteers.
This biological collection will include a sample of 2 dry tubes and 2 EDTA tubes. A haematological assessment (CBC, platelets, reticulocytes, Chr (hemoglobin content of reticulocytes), TP-INR, AST, ALT, GGT), measurement of biological markers of iron metabolism (ferritin, serum iron, CRP, transferrin, soluble receptors transferrin, transferrin saturation coefficient) as well as a creatinine assay to validate the normality of renal function in healthy volunteers (GFR established from the MDRD formula), a complete ionogram and a phosphocalcic balance being given the interactions in the dialysis patient (but also in normal subjects) between iron metabolism and phosphocalcic metabolism (calcemia, phosphoremia, PTH, 25OHD3, 1,25OH2D3) will be performed. We will also study the links between iron overload in dialysis patients and the modulation of the synthesis of parathyroid hormone (intact PTH), FGF23, alpha Klotho and sclerostin. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05031013 -
Trace Elements Concentration in Dialysis
|
||
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT01685372 -
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
|
Phase 2 | |
Active, not recruiting |
NCT01394770 -
Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients
|
Phase 4 | |
Completed |
NCT00537979 -
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
|
Phase 4 | |
Completed |
NCT00506441 -
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
|
Phase 3 | |
Completed |
NCT05415969 -
CKD-aP Among Adults on Dialysis in Switzerland
|
||
Recruiting |
NCT04024007 -
Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits
|
||
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT01693263 -
Outcome of BCF Access in Hemodialysis Patients
|
||
Completed |
NCT01421771 -
Blood Pressure in Dialysis Patients
|
N/A | |
Active, not recruiting |
NCT01065389 -
Resistance Training in Intradialysis Patients
|
Phase 2 | |
Completed |
NCT00544492 -
Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT03910426 -
Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
|
||
Completed |
NCT04667741 -
Post-dialysis Recovery Time and Affecting Factors Between Turkey and Portugal
|
||
Completed |
NCT04565522 -
Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers
|
||
Completed |
NCT04655989 -
A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System
|
N/A | |
Completed |
NCT05125848 -
Clinical Evaluation of the CM-1500 During Hemodialysis
|
N/A | |
Completed |
NCT04633915 -
Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.
|